Shareholders


Audited by PwC

Novozymes’ common stock consists of two types: A shares and B shares, both with a nominal value of DKK 10 per share. All A stock is held by Novo A/S, and an A share carries 10 times as many votes as a B share.

A stock B stock Total
Common stock (DKK)

107,487,200

542,512,800

650,000,000

Number of shares

10,748,720

54,251,280

65,000,000


Number of votes

1,074,872,000

542,512,800

1,617,384,800

Voting rights (%)

66.5

33.5

100

 

At the end of 2010, Novo A/S held 25.5% of the total outstanding common stock and, through its holding of the A stock and a proportion of the B stock (5,826,280 shares), controlled 70.1% of the votes. Novo A/S is wholly owned by the Novo Nordisk Foundation, and so Novozymes is included in the consolidated financial statements of the Novo Nordisk Foundation. Novo A/S is domiciled in Hellerup, Denmark.

Novozymes had roughly 47,000 shareholders at the end of the year, of whom around 98% were private investors, mainly in Denmark. Thirty institutional shareholders owned approximately 60% of the B stock (this includes Novozymes A/S’ holding of treasury stock and Novo A/S’ holding). Investors outside Denmark held approximately 66%.

Novozymes held 3.8% of the B stock, equivalent to 3.2% of the total number of shares outstanding.

Under the Danish Companies Act, shareholders must notify the company if they hold 5% or more of the company’s common stock. No shareholders, except Novo A/S, held more than 5% of Novozymes’ common stock.

Financial calendar

Group financial statement for 2010

  January 21, 2011

Annual Shareholders' Meeting

      March 2, 2011

Group financial statement for the first quarter of 2011

 April 29, 2011

Group financial statement for the first half of 2011

 August 11, 2011

Group financial statement for the first nine months of 2011   

 October 28, 2011

Group financial statement for 2011

 January 19, 2012

My Report

0 pages added

MyReport Videos
Novozymes’ Executive Management reflects on the past year, the past decade, and what lies ahead.
Novozymes’ Executive Management group on 2010

SEE ALL VIDEOS
SHAREHOLDER DISTRIBUTION OF B COMMON STOCK
FusionCharts.
Denmark (20%)
North America (16%)
UK (38%)
Novo A/S (11%)
Own shares (4%)
Rest of world (2%)
Rest of Europe (9%)
Contact Investor Relations
CLICK TO READ MORE...